HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Huaqin (A/H Listing) - Low Profit Margin Is a Pain Point Due to Flaws in Business Model

Pre-IPO Shanghai Xizhi Technology (PHIP Update)-The Business, Peer Comparison, Thoughts on Valuation

Pre-IPO Huaqin (3296 HK) - Thoughts on the IPO Pricing and the Outlook

Pre-IPO Zhejiang Shimai Pharmaceutical - It Might Never Be Possible to Make Money

Pre-IPO Anhui Huaheng Biotechnology (A/H Listing) - The Business, Outlook, and Thoughts on Valuation

Pre-IPO Shenzhen Mindray Bio-Medical Electronics (A/H Listing) - The Headwinds Still Exist

Equity Capital Markets

<ul>
<li>Whether COL's strategy of "burning money to expand scale" can smoothly transition to a stable profit-making stage is highly uncertain. At present, the profit turning point remains unclear.</li>
<li>Investors have reason to worry when the trend of "AI + micro dramas" weakens, COL may make strategic shifts, resulting in current investment not being able to generate long-term assets.</li>
<li>Although COL's IP library is massive, the scarcity/commercial value of top IPs aren't on the same level as <a href="https://www.smartkarma.com/entities/china-literature-ltd" target="_blank" data-smartkarma-citation="entities:24388:1" rel="noopener">China Literature</a>. So, the "ceiling" for COL’s IP derivative development is lower.</li>
</ul>


Whether COL's strategy of "burning money to expand scale" can smoothly transition to a stable profit-making stage is highly uncertain. At present, the profit turning point remains unclear.
Investors have reason to worry when the trend of "AI + micro dramas" weakens, COL may make strategic shifts, resulting in current investment not being able to generate long-term assets.
Although COL's IP library is massive, the scarcity/commercial value of top IPs aren't on the same level as China Literature. So, the "ceiling" for COL’s IP derivative development is lower.


Chineseall Digital Publishing (300364 CH)

Pre-IPO COL Global/Chineseall Digital Publishing (A/H Listing)- The Profit Model Is Facing Challenge